Biotech and Pharmaceuticals
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise pre-released its 2026 forecast late Tuesday, sending shares tumbling. Novo Nordisk’s stock plummeted 18% in Copenhagen early Wednesday, tracking losses seen in its American depositary shares on Tuesday and more than wiping out gains seen so far […]
Read More
Novo Nordisk shares tumble after company forecasts sales declines this year
Novo Nordisk‘s U.S. shares plummeted Tuesday after the company said it sees sales and profit growth declining this year, hit by lower prices in the U.S. and loss of exclusivity for its blockbuster Wegovy and Ozempic in China, Brazil and Canada. The company published the forecast as it reported full-year 2025 sales, ahead of the […]
Read More
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic […]
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]
Read More
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026. Oscar Molina | CNBC Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December. […]
Read More
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation
Pharma giant AstraZeneca will list on the New York Stock Exchange on Monday, days after it announced big commitments on the other side of the world. Like the rest of Big Pharma, the company has a balancing act. It wants a close relationship with the U.S., its biggest market, and the listing is intended to […]
Read More
Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that […]
Read More
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Friday said it will spend more than $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity […]
Read More
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
Drugmakers Roche and Sanofi’s latest earnings were largely as expected, with the companies talking up the potential of experimental medicines ahead of a looming “patent cliff” for Big Pharma. Both companies’ stocks were down less than 1% on Thursday after reporting earnings before the bell. They are both among the pharmaceutical companies that could see […]
Read More
UnitedHealth posts modest earnings beat, soft revenue guidance as insurer plots turnaround
UnitedHealth Group Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, Dec. 31, 2025. Michael Nagle | Bloomberg | Getty Images UnitedHealth Group on Tuesday posted a modest fourth-quarter earnings beat, but issued soft revenue guidance, as the parent company of the nation’s largest private insurer […]
Read More